A Phase 1b, Single-blind, Placebo-controlled, Adaptive Design, Outpatient Trial to Assess the Effects of Single Oral Tablet Doses of OPC-214870 on Photic-induced Paroxysmal Electroencephalogram Responses in Subjects Who Have Demonstrated Photoepileptiform Discharges on Electroencephalogram With or Without Seizures
Latest Information Update: 26 Aug 2022
At a glance
- Drugs OPC 214870 (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 19 Aug 2022 Status changed from recruiting to completed.
- 14 May 2021 Planned End Date changed from 1 Mar 2021 to 1 Aug 2021.
- 14 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Aug 2021.